Recro Pharma (REPH) Tops Q2 EPS by 29c, Revenues Beat; Raises FY19 Revenue Guidance
Tweet Send to a Friend
Recro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.13), $0.29 better than the analyst estimate of ($0.42). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
